5α-reductase inhibitors impact prognosis of urothelial carcinoma

BACKGROUND: 5α-reductase inhibitors (5-ARIs) inhibit the pathway of converting the testosterone to dihydrotestosterone and are widely used in benign prostatic hyperplasia patients. Since androgen receptor activation may play a role in urothelial tumorigenesis, we conducted this retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chien-Sheng, Li, Ching-Chia, Juan, Yung-Shun, Wu, Wen-Jeng, Lee, Hsiang-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488389/
https://www.ncbi.nlm.nih.gov/pubmed/32917158
http://dx.doi.org/10.1186/s12885-020-07373-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488389/
https://www.ncbi.nlm.nih.gov/pubmed/32917158
http://dx.doi.org/10.1186/s12885-020-07373-4

Ejemplares similares